Elevation Oncology (NASDAQ:ELEV) Given “Outperform” Rating at Wedbush

Elevation Oncology (NASDAQ:ELEV)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $8.00 price target on the stock. Wedbush’s price objective points to a potential upside of 105.13% from the stock’s previous close.

A number of other analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Elevation Oncology in a research note on Tuesday, April 9th. JMP Securities reissued a “market outperform” rating and set a $7.00 price target on shares of Elevation Oncology in a research report on Thursday, March 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Elevation Oncology currently has an average rating of “Buy” and a consensus price target of $7.25.

Elevation Oncology Price Performance

NASDAQ:ELEV traded up $0.08 during trading hours on Friday, hitting $3.90. The company’s stock had a trading volume of 226,966 shares, compared to its average volume of 2,507,804. Elevation Oncology has a twelve month low of $0.36 and a twelve month high of $5.89. The stock has a fifty day simple moving average of $4.36 and a 200-day simple moving average of $2.37. The company has a debt-to-equity ratio of 0.55, a current ratio of 21.22 and a quick ratio of 21.22. The company has a market capitalization of $213.10 million, a P/E ratio of -2.62 and a beta of 1.52.

Elevation Oncology (NASDAQ:ELEV) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, analysts anticipate that Elevation Oncology will post -0.87 EPS for the current fiscal year.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.